- BySeeking Alpha-
Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Utilities, Technology and Consumer Goods sectors led shares higher while losses in the...
Gainers:Mackinac Financial (MFNC) +56%. NovoCure (NVCR) +42%. Losers: Brooklyn ImmunoTherapeutics (BTX) -19%.Avenue Therapeutics (ATXI) -19%.AdaptHealth (AHCO) -18%.
1. Co-Diagnostics (NASDAQ:CODX) had an exceptional day on Wednesday. I have been telling you that this swing was ready to take off and it did. Once it got through the level around...
As of late, it has definitely been a great time to be an investor in vTv Therapeutics Inc. ( (NASDAQ:VTVT) ). The stock has moved higher by 32.4% in the past month, while it is...
The Medical sector has witnessed a fairly good run in this earnings cycle so far. Per the Earnings Trend report (published last week), 76.9% of the companies have reported earnings...
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.